The Filing Desk

Cardiff Oncology vs ImageneBio

Cardiff Oncology CRDF · ImageneBio IMA · Biotechnology

ImageneBio reported revenue of $1 million in fiscal 2025, 1.3 times Cardiff Oncology's $1 million in fiscal 2025. Cardiff Oncology's revenue fell 13.2% in its latest year, and ImageneBio's fell 77.1%. Cardiff Oncology had an operating margin of -8256.3%, against -6056.4% at ImageneBio.

Side by side

Cardiff OncologyImageneBio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth−13.2%−77.1%
Revenue growth a year, last 5 years8.4%−38.6%
Gross margin——
Operating margin−8,256.3%−6,056.4%
Net margin−7,732.0%−5,668.6%
Free cash flow−$38M—
Free cash flow margin−6,402.5%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count40.3%303.7%
Last close$0.89$3.98
P/E at the last close——
Insider trades, last 12 monthsbought $1.1 million, sold $0bought $95,840, sold $17,334
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cardiff OncologyImageneBio
Operating margin
Percent of revenue
Cardiff OncologyImageneBio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cardiff OncologyImageneBio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cardiff Oncology and ImageneBio pages.